Well this is a basic mass bulk cycle and one ive tried many times before with many different brands (Human Grade and UG labs) so i know what results i should be getting while on cycle.
Well first impressions start with the Dbol , i was only using a low dose @ 30mg each day but it still seemed very effective, after the 1st day i noticed the pump in my biceps and the fuller feeling i normally get in my arms when on dbols, by the third week i had gained a solid 4lbs through eating a good clean diet.
Only problem with these dbols is that by the middle of week 4 i had terrible back pumps even though i was running it at a low dosage.
Ive run Dbols before at 50mg ED for 4 weeks and not got these back pumps so im unsure why i got them at a lower dose, maybe something lacking in my diet or maybe the tabs where overdosed ?
The GP Test Enanth was a painless injection and quite smooth even with a 25g needle, i could feel the test kicking in by the end of week 3 , i got a sense of well being and balls like peanuts lol !
The Decca was also painless and smooth , by the end of week 8 i had but on 10lbs i did have a fair amount of water bloat but that was to be expected, i did also notice that by week 5 i had quite alot of back acne but again this is normal for me and was expected.
At the end of the 12 weeks i had gained a impressive 16lbs but after my PCT i kept 12lbs , still quite impressive, i looked alot fuller and was very happy with the results.
So all in all apart from the back pumps on the dbol Geneza scored quite highly with me!
It was a good cycle and i was happy with the results , i wouldnt say Geneza where Human grade quality but they are a very close UG lab version !
This press release contains forward-looking statements, including statements regarding our research and development program and collaboration with Debiopharm and the prospects for further clinical trials and commercialization of the DX-890 compound. Statements that are not historical facts are based on our current expectations, beliefs, assumptions, estimates, forecasts and projections about the industry and markets in which Dyax competes. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors which may affect the future of this collaboration and commercialization of DX-890 include the following risks: our dependence on the expertise, effort, priorities and contractual obligations of Debiopharm in the development, clinical trials, manufacture, marketing, sales and distribution of DX-890; DX-890 may not show therapeutic effect or an acceptable safety profile in clinical trials or could take a significantly longer time to gain regulatory approval than we expect or may never gain approval; DX-890 may not gain market acceptance; our ability to obtain and maintain intellectual property protection for our products and our technologies; the development of technologies or products superior to DX-890; and other risk factors described or referred to in our most recent Annual Report on Form 10-K and other periodic reports filed with the Securities and Exchange Commission. Dyax cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Dyax undertakes no obligations to update or revise these statements, except as may be required by law. Dyax specifically disclaims responsibility for statements made by Debiopharm and the paragraph of information describing Debiopharm that was provided by Debiopharm.
The animal health applications of ivermectin have been reviewed (Benz, G. W., et at., in Ivermectin and Abamectin, Campbell, W. C., ed., Springer-Verlag, New York (1989), pp. 215-295, incorporated herein by reference). Ivermectin has been used in oral formulations such as in oral solution as for the treatment and control of gastrointestinal nematodes, lungworms, grubs, and sucking lice. The agent has also been topically applied in a liquid form for the treatment and control of gastrointestinal nematodes, lungworms, grubs, sucking and biting lice, chorioptic and sarcoptic mange mites and as an aid in control of ticks. A sustained release bolus form has also been used (Williams, J. C. et al., Am. J. Vet. Res. 53:793-795 (1992)) to deliver ivermectin at a steady-state rate. The boluses are designed to be delivered orally into the distal pharynx or anterior esophagus. In sheep, a liquid form has been used for the treatment and control of gastrointestinal nematodes, lungworms, nasal bots and itch mites. An injectable formulation has also been used in sheep. This was administered subcutaneously and was indicated for the treatment and control of gastrointestinal nematodes, lungworms, nasal bots, mange mites and itch mites. A liquid formulation for goats has been used as in sheep. Injectable formulations have also been used in pigs as a treatment against gastrointestinal roundworms, lungworms, kidney worms, lice and mites.